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Objectives
To quantify the health-related quality of life (HRQoL) of
patients with bladder cancer around the time of diagnosis and
to test the hypotheses of a two-factor model for the HRQoL
questionnaire QLQ-C30.
Methods
From participants in the Bladder Cancer Prognoses
Programme, a multicentre cohort study, sociodemographic
data were collected using semi-structured face-to-face
interviews. Answers to the QLQ-C30 were transformed into a
scale from 0 to 100. HRQoL data were analysed in
multivariate analyses. The hypothesized two-factor (Physical
and Mental Health) domain structure of the QLQ-C30 was
also tested with confirmatory factor analyses (CFA).
Results
A total of 1160 participants (78%) completed the
questionnaire after initial visual diagnosis and before
pathological confirmation. Despite non-muscle-invasive
bladder cancer (NMIBC) being associated with a higher
HRQoL than carcinoma invading bladder muscle, only the
domain Role Functioning was clinically significantly better in
patients with NMIBC. Age, gender, bladder cancer stage and
comorbidity all had a significant influence on QLQ-C30
scores. The CFA showed an overall good fit of the
hypothesized two-factor model.
Conclusion
This study identified a baseline reference value for HRQoL
for patients with bladder cancer, which allows better
evaluation of any changes in HRQoL as disease progresses or
after treatment. In addition, a two-factor (Physical and
Mental Health) model was developed for the QLQ-C30.
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Introduction
Bladder cancer ranks as the 10th most frequently diagnosed
cancer worldwide [1,2]. In the UK, the disease accounts for
~10 300 new cases and 5300 deaths per year (Cancer
Research UK Cancer Statistics). The majority of patients (75–
80%) present with non-muscle-invasive bladder cancer
(NMIBC) [3]. Although not immediately life-threatening in
the majority of cases, recurrence and progression of NMIBC
remain significant issues, with up to 55% of patients
experiencing recurrence within 5 years of diagnosis [4].
Current guidelines therefore recommend long-term
surveillance [5,6]. With the UK prevalence of NMIBC
estimated at 46 500 by Cancer Research UK, at any one time
there will be at least 40 000 patients requiring surveillance
episodes at least once per year.
Typically, surveillance comprises outpatient flexible
cystoscopy, with or without urine cytology [7,8]. For patients
with low-risk NMIBC, European Association of Urology
guidelines recommend follow-up cystoscopy and urine
cytology at 3 and 12 months after transurethral resection of
bladder cancer, and then annually thereafter until 5 years.
Patients with high-risk NMIBC undergo more intensive
surveillance: every 3 months for the first 2 years, then every
6 months for the following 3 years, and annually thereafter,
most likely for the rest of their lives [9]. If recurrence is
detected, the tumour is resected and subsequent surveillance
will start again, with the frequency determined by the risk
category of the recurrence.
Each surveillance cystoscopy and urine cytology episode costs
at least £533 [10]. As a result, bladder cancer is the most
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costly cancer to treat on a per-patient basis from diagnosis to
death [11,2]. Furthermore, cystoscopy itself significantly
increases the burden of disease, as it is an invasive procedure
that causes pain and discomfort in about one-third of
patients [12].
As survival amongst patients with NMIBC is high compared
with other cancers, and long-term follow-up is required, the
disease can be considered a chronic disease [13]; therefore,
health-related quality of life (HRQoL) plays an important
role. To date, however, most HRQoL research has focused on
carcinoma invading bladder muscle (MIBC) and, in
particular, the differences between different urinary diversions
after radical cystectomy [14–16], but the results are difficult
to interpret, as there are often no baseline reference values for
comparison. For patients with MIBC, although HRQoL is
affected more severely as a result of more radical treatments,
a higher chance of metastasis, and worse overall prognosis, it
is still an important measure. The few studies that have
reported on HRQoL in patients with NMIBC contradict each
other [17–21]. In addition to the evidence being sparse,
studies have often been hindered by small sample sizes, non-
validated HRQoL questionnaires, and patient populations that
are heterogeneous in terms of duration of follow-up, previous
diagnoses of bladder cancer, and number of recurrences or
progression.
Additionally, most studies do not take baseline HRQoL into
account, which is important for the evaluation of any changes
in a patient’s HRQoL attributable to disease or treatment.
Bladder cancer is a complex disease that often goes
undetected for an extended period of time, especially in
women [22]. This could imply that bladder cancer may have
already affected patients’ HRQoL at or around the time of
diagnosis, and their HRQoL will not necessarily be the same
as that of the general population. It is, therefore, important to
study HRQoL at or around the time of bladder cancer
diagnosis.
One of the reasons that HRQoL is not often taken into
account in studies may result from the complex nature of the
questionnaires used to measure HRQoL. More specifically, the
commonly used HRQoL questionnaire, the QLQ-C30 [23],
has 15 separate domains that need to be compared with each
other in order to provide a complete assessment of patients’
HRQoL. Higher-order models would resolve the issue of too
many individual domains. Gundy et al. [24] examined several
of these models, including one- and two-factor models, and
suggested that a two-factor model divided into Physical and
Mental health provided the best statistical fit.
The aim of the present study was to be the first to quantify
and compare HRQoL at or around the time of diagnoses in
patients with NMIBC and MIBC separately. Additionally, the
study tested the hypothesis of a two-factor model for the
QLQ-C30.
Methods
Study Design
The present study is part of the West Midlands’ Bladder
Cancer Prognoses Programme (BCPP), a multicentre cohort
study in the West Midlands, UK (ethics reference: 06/
MRE04/65; clinicaltrials.gov registration number:
NCT00553215). Details of the study have been published
previously [25]. Briefly, adults (age ≥18 years) presenting at
haematuria clinics in nine participating urology centres
within the region were enrolled on the basis of abnormal
cystoscopic findings suggestive of bladder cancer. Those who
had a previous diagnosis of cancer of the urethra, bladder,
ureter or renal pelvis within the last decade, HIV infection, or
any other condition that might interfere with the safety of the
participant were excluded. Enrolment took place between 19
December 2005 and 21 April 2011. All participants provided
written informed consent before they were included in the
study.
Data Collection
At the time of diagnoses, semi-structured face-to-face
interviews were used by trained research nurses to collect
information on socio-demographics, health-related lifestyle,
medical and drug history, dietary intake, social support and
quality of life. The European Organization for the Research
and Treatment of Cancer (EORTC) QLQ-C30 v3 was used
for the collection of the HRQoL data. The transformation of
the scores is described in detail elsewhere [26]. The QLQ-C30
is a validated questionnaire specifically developed for
measuring HRQoL in people with cancer. It has 30 items
assessing 15 domains (one global HRQoL domain, five
functional domains, and nine symptom domains). Briefly, the
answers are converted into a score from 0 to 100, where 100
is the best quality of life and 0 is the worst for all domains
except the nine symptom domains, for which 100 is the most
problematic symptom and 0 is no symptoms at all. A
difference of 10 points or more is considered clinically
relevant [27].
The medical records of each patient were reviewed by trained
research nurses, and clinicopathological characteristics of
bladder cancers at diagnosis were prospectively gathered on
dedicated case report forms. This comprised pT stage
(according to the TNM 6th edition 2002 classification system
[28]), grade (according to the WHO 1973 system [29]), size
of the largest tumour, the number of visible tumours, and
comorbidities. Where early re-resection (within 3 months
after first surgery for bladder cancer) indicated an invasive
tumour (≥pT2) contrary to the original assessment, then re-
resection pT stage was recorded as the pT stage at diagnosis.
Stage was recoded into a numerical outcome variable suitable
for analyses by coding pTa tumours with a value ‘1’ and all
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other stages in sequence. Comorbidities were defined as any
pre-existing medical conditions, or conditions present at the
time of bladder cancer diagnosis. For this study, the number
of comorbid conditions for each participant was recoded as 0,
1, 2, 3, 4, 5, >5. In addition, a separate variable was generated
to recode stage as NMIBC (<pT2) and MIBC (pT2+).
Statistical Analyses
Mean and SD values were calculated for all domains of the
QLQ-C30 to reflect reference values for patients with NMIBC
and those with MIBC. The effect of age, gender, stage and
comorbidity on the 15 HRQoL domains from the QLQ-C30
was analysed using multivariate linear regression models. For
this analysis, gender (male, female), stage (pTis, pTa, pT1,
pT2, pT3, pT4) and comorbidity (0, 1, 2, 3, 4, 5, >5) were
included as categorical variables. Statistical differences
between the HRQoL domains and NMIBC and MIBC were
tested using the two-group mean-comparison (ANOVA). A
factor analysis was used to detect the underlying hypothesized
two-factor model, a value of 0.45 was used as the cut-off
value for factor loadings. We used confirmatory factor
analyses (CFA) to test our hypothesis of a two-factor model.
The two overall HRQoL items were not included in the CFA,
as this domain (overall HRQoL) is not considered to be part
of HRQoL but rather a global domain.
Results
Sociodemographics
During the enrolment period, patients with symptoms related
to bladder cancer accompanied by cystoscopically suspicious
lesions were recruited. Out of 1534 recruited participants,
1183 were subsequently diagnosed with bladder cancer. Of
these, 1160 had completed the questionnaire before they
knew the histologically confirmed diagnosis and could
therefore be included in the analyses for the present study.
The majority of the study cohort were men (n = 906, 78.1%)
and the mean (range) age was 70.4 (26–95) years. Over half
of the patients were currently in a relationship (n = 728,
62.8%). Most of the patients presented with NMIBC (n =
890, 76.7%), with pTa the most common tumour stage (n =
575, 49.6%). In addition, 27.4% of the patients had more than
five comorbidities, as can be seen in Table 1.
Health-Related Quality of Life in Patients with Non-
Muscle Invasive vs Muscle-Invasive Bladder Cancer
The mean (SD) overall quality of life score was 69 (23) in
patients with NMIBC and 61 (24) in those with MIBC. The
functional domains for patients with NMIBC ranged from 76
to 86, whilst in patients with MIBC the same domains ranged
from 72 to 81. In both groups (NMIBC and MIBC) the worst
symptoms were Fatigue and Insomnia. In general, there were
few differences in HRQoL between patients with NMIBC and
those with MIBC, with none of the scores differing by at least
10 points, except for Role Functioning (Table 2). It was
notable that patients with MIBC always scored lower than
those with NMIBC on the QLQ-C30, with a statistically
significant difference in seven domains (Global HRQoL,
Physical Functioning, Role Functioning, Social Functioning,
Fatigue, Pain, Dyspnoea, Insomnia, and Appetite Loss). The
lowest scoring domain in both the NMIBC and MIBC groups
was Global HRQoL (69/100 and 61/100, respectively). Scores
in all other domains were >75 in the NMIBC group and >65
in the MIBC group.
From Table 3, it is clear that age had a statistically significant
effect on nearly all functional HRQoL domains, except for
Social Functioning. Additionally, age had a statistically
Table 1 Socio-demographic characteristics of study participants.
Demographic No. of patients %
Total 1160 100
Men 906 78.1
Women 254 21.9
Age, years
Mean (SD) 70.4 (10.9)
Range 26–95
Marital status
With partner 728 62.8
Without partner 344 29.7
Missing 88 7.5
Smoking status
Current 228 19.7
Former 612 52.8
Never 217 18.7
Missing 103 8.8
Tumour stage
pTis 14 1.2
pTa 575 49.6
pT1 301 25.9
pT2 233 20.1
pT3 1 0.1
pT4 17 1.5
Missing 19 1.6
Tumour grade
1 254 21.9
2 336 29.0
3 540 46.5
Missing 30 2.6
NMIBC 890 76.7
MIBC 251 21.6
Missing 20 1.7
Comorbidities
0 92 7.9
1 185 16.0
2 156 13.4
3 176 15.2
4 118 10.2
5 115 9.9
>5 318 27.4
MIBC, carcinoma invading bladder muscle; NMIBC, non-muscle-invasive bladder
cancer. Missing values are not explicitly reported.
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significant effect on Fatigue, Dyspnoea, Insomnia,
Constipation, Diarrhoea and Financial Difficulties. Increased
age was detrimental in all statistically significant domains
except for Financial Difficulties, Insomnia, Diarrhoea and
Emotional Functioning. The biggest effect was found in the
Physical Functioning domain, where a 10-year increase in age
would decrease the score by 4 points. Women had worse
outcomes on every statistically significantly different HRQoL
domain compared with men. Gender was the only variable
that had a clinical impact (>10 points difference), for
instance, on the domain Insomnia where men scored 12.19
points higher. All domains of HRQoL were negatively
associated with the number of comorbidities. Patients with
NMIBC scored better in every HRQoL domain of QLQ-C30
compared to those with MIBC, although this was not always
a statistically significant difference, nor were any of the
differences clinically significant.
Confirmatory Factor Analyses of the Two-Factor
Model
The factor analyses showed that eight items (items 11, 13, 14,
15, 16, 17, 25 and 28) did not fit the two-factor model (factor
loading <0.45), most of which pertained to the one-item
domains such as Sleep (item 11), Appetite Loss (item 13),
Constipation (item 16), Diarrhoea (item 17), and Financial
Difficulties (item 28), as well as the two-item domains such
as, Nausea and Vomiting (items 14 and 15), and Cognitive
Functioning (items 20 and 25). The domains Fatigue (items
10, 12, 18), Physical Functioning (items 1–5), Role
Functioning (items 6 and 7), Dyspnoea (item 8), Pain (item 9
and 19), and Social Functioning (items 26 and 27) loaded
onto factor 1 (Physical Health) and the domains Cognitive
Functioning (item 20), and Emotional Functioning (items 21–
24) loaded onto factor 2 (Mental Health). The sample size for
the CFA, using the Physical/Mental Health model discussed
above, was 1036; 124 patients had missing data for at least
one of the 28 items. The comparative fit index was 0.97, the
Tucker–Lewis fit index was 0.95, and the root mean squared
error of approximation was 0.05 (90% CI 0.048–0.057; P-close
= 0.20). In addition, the coefficient of determination was 0.95
(interpreted as 95% of the variance in the observed variables
being explained by the model) and the standardized root
mean squared residual was 0.034.
Table 2 Health-related quality of life as measured by the European
Organization for Research and Treatment of Cancer questionnaire QLQ-
C30 for non-muscle-invasive and muscle-invasive bladder cancer
separately.
QLQ-C30* NMIBC (N = 890) MIBC (N = 251) P
Mean SD Mean SD
Global HRQoL 69 23 61 24 <0.001
Functional domains (0 worst functioning; 100 best functioning)
Physical
functioning
84 20 79 23 0.005
Role functioning 83 28 72 34 <0.001
Emotional
functioning
76 22 75 23 0.536
Cognitive
functioning
84 19 81 23 0.036
Social functioning 86 23 81 28 0.003
Symptom domains (0 No symptoms; 100 worst symptoms)
Fatigue 76 23 69 28 <0.001
Nausea and
vomiting
96 11 94 13 0.079
Pain 83 25 76 30 <0.001
Dyspnoea 85 24 81 29 0.015
Insomnia 76 31 67 35 <0.001
Appetite loss 89 22 81 31 <0.001
Constipation 88 23 83 28 0.012
Diarrhoea 94 16 93 18 0.471
Financial difficulties 95 17 93 20 0.147
HRQoL, health-related quality of life; MIBC, carcinoma invading bladder muscle;
NMIBC, non-muscle-invasive bladder cancer. P value is for chi-squared test. *Score
range 0–100.
Table 3 Multivariate linear regression of age, gender, stage and comorbidity on each health-related quality of life domain.
QLQ-C30 domains Age Gender Social support Stage Comorbidity
b P b P b P b P b P
Global HRQoL 0.07 0.015 4.49 0.007 0.30 <0.001 6.85 <0.001 2.83 <0.001
Physical F 0.42 <0.001 4.83 0.001 0.15 <0.001 1.77 0.220 3.21 <0.001
Role F 0.26 0.002 1.19 0.577 0.26 <0.001 8.16 <0.001 3.26 <0.001
Emotional F 0.28 <0.001 6.99 <0.001 0.20 <0.001 0.77 0.640 1.78 <0.001
Cognitive F 0.09 0.024 0.61 0.685 0.19 <0.001 1.78 0.236 1.82 <0.001
Social F 0.01 0.836 2.87 0.113 0.22 <0.001 4.03 0.026 2.24 <0.001
Fatigue 0.12 0.029 5.26 0.002 0.26 <0.001 5.02 0.004 3.61 <0.001
Nausea and vomiting 0.06 0.072 5.33 <0.001 0.04 0.027 1.23 0.166 0.60 0.002
Pain 0.02 0.824 4.01 0.037 0.25 <0.001 5.43 0.005 3.56 <0.001
Dyspnoea 0.21 0.004 0.06 0.972 0.09 0.021 2.64 0.153 3.24 <0.001
Insomnia 0.37 <0.001 12.19 <0.001 0.25 <0.001 8.41 <0.001 3.22 <0.001
Appetite loss 0.02 0.771 7.81 <0.001 0.25 <0.001 7.06 <0.001 1.15 0.003
Constipation 0.30 <0.001 2.50 0.171 0.13 0.002 3.02 0.098 1.28 0.001
Diarrhoea 0.11 0.020 2.72 0.029 0.11 <0.001 0.67 0.592 1.14 <0.001
Financial difficulties 0.24 <0.001 0.07 0.958 0.20 0.03 2.17 0.097 1.05 <0.001
HRQoL, Health-related quality of life. b, unstandardized coefficient of the multivariate linear regression analyses; F represents a functional domain.
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The differences between Physical/Mental Health, stratified by
the sociodemographic characteristics, are shown in Table 4.
Again, there were differences among the various categories
within each stratum, amongst, differences between the 1)
most invasive tumour stage pT4 (n = 17) and non-invasive
tumour stage pT1 or below (n = 890), 2) the most
comorbidities (>5) and the non-comorbidity, were both larger
than 10 points. Apart from tumour stage, the biggest
difference was observed in the age strata, where patients aged
>75 years and those aged <65 years differed by 8 points for
Physical Health. The Physical and Mental health domains had
a good correlation (r = 0.82).
Discussion
To our knowledge, this study is the first to investigate
HRQoL in patients with NMIBC and those with MIBC at this
specific time point: around the time of diagnosis.
Interestingly, the HRQoL of both the NMIBC and MIBC
groups was relatively high: none of the mean values for each
domain fell below 60, and patients in both groups even
scored >90 in a number of domains. In addition, we
identified that reduced HRQoL was common in women and
in patients with the features of aging and advanced tumour
stage. Furthermore, patients with bladder cancer who had
more comorbid conditions were much more likely to report
poor HRQoL.
It is important to recognize that people with bladder cancer
may have a different baseline HRQoL compared with the
general population, as the disease may have already had an
impact at or around the time of diagnosis. No reference data
are available for the general population in the UK; however,
the mean scores of HRQoL (QLQ-C30) for the present study
population were lower than data for the general populations
of Germany, Norway, Sweden and Slovenia [30–33], but
higher than the general population of the USA [34]. It is
therefore, possible that HRQoL reference values for patients
with bladder cancer depend on cultural factors; for example,
Scandinavian populations have a high standard of living [35].
This could lead to a greater difference in HRQoL among
patients with bladder cancer from different countries.
Although it is more likely that cancer treatment (i.e. surgery,
chemotherapy, radiation) will have an effect on HRQoL, an
immediate change to an individual’s HRQoL at diagnosis may
depend on the type of cancer. Compared with people in the
UK diagnosed with several other cancer types, including
breast [36], lung [37,38], colorectal [39], head and neck [40],
malignant mesothelioma [41], endometrial cancer [42], oral
and oropharyngeal cancer [43], the patients with bladder
cancer in the present study had higher HRQoL scores for all
domains, which might be attributable to the poorer prognoses
for these other cancer types.
No clinically significant differences (>10 points) in HRQoL
domains were found between patients with NMIBC and those
with MIBC, except for Role Functioning. This might be
attributable to the unique time point at which the
questionnaire was administered, namely, before
histopathological confirmation of diagnosis. Previous studies
have found significantly worse HRQoL values between 3 and
18 months after diagnosis [44–46]. However, in the present
study it was apparent that the disease had already affected
patients such that a difference between patients with NMIBC
and MIBC could be identified in the Role Functioning
domain (indicating that patients with MIBC feel more
restricted in fulfilling their role in society) even at this early
time point in the patient pathway. Nevertheless, patients with
MIBC did not report higher pain levels or more restrictive
Physical Functioning, possibly in contrast to what might be
expected [47].
As demonstrated by multivariate analyses, age, gender, stage
and comorbidity significantly influenced HRQoL. Overall,
increased age, stage and comorbidity quantities were related
to worse HRQoL. The tendency for women with bladder
Table 4 Physical and mental health scores across the different
sociodemographic variables.
Demographic Physical health Mental health
Mean SD Mean SD
Gender
Male 80*** 20 81* 17
Female 75 22 78 19
Age
≤65 years (1) 83*** 20 81* 19
66–75 years (2) 80 20 82 16
>75 years (3) 75 21 79 18
Marital status
With partner 75*** 23 79 20
Without partner 81 21 81 17
Smoking status
Current 78* 23 79 21
Former 78 21 80 18
Never 82 20 83 17
Tumour stage
pTis 82*** 21 85** 13
pTa 81 19 82 16
pT1 79 21 81 18
pT2 75 23 78 18
pT3 73 – 87 –
pT4 69 32 71 25
NMIBC 80*** 20 81* 17
MIBC 74 23 78 19
Comorbidity
0 94*** 14 87*** 17
1 93 13 86 15
2 88 17 86 16
3 82 19 80 17
4 83 20 81 18
5 79 22 80 17
>5 70 25 73 23
MIBC, carcinoma invading bladder muscle; NMIBC, non-muscle-invasive bladder
cancer. *P < 0.05; **P < 0.01; ***P < 0.001.
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cancer to have a lower HRQoL than men with bladder cancer
is consistent with some study findings in the general
population [30,31,48,49] and in other cancer types [50,51],
and also with earlier population studies showing that, on
average, women reported a higher proportion of health
problems [52].
It was not surprising that age was observed to be an
important factor for defining HRQoL. Older participants
experienced a deterioration for most of the functional scales,
except for Emotional Functioning which was slightly
increased in older people, and Social Functioning which was
found to be unrelated to age. These findings are in line with
earlier studies in general populations from other European
countries [30–33].
Comorbidity may in itself influence HRQoL because of the
unique physical impact of the specific health condition and
may thus play an important role when assessing HRQoL at
the time of bladder cancer diagnosis. Indeed, we observed
that comorbidity related to a decreased HRQoL, indicating
that the presence of comorbidity before bladder cancer
diagnosis may already have caused decrements in HRQoL.
Since a more advanced tumour stage might cause more fear
of progression and death, it was not unexpected to observe
that tumour stage negatively affected HRQoL. Previous
studies in other cancer types (e.g. oropharyngeal cancer [53]
and prostate cancer [54]) confirmed this finding. Both
tumour-specific features and comorbidity should be evaluated
in patients with bladder cancer for better understanding of
HRQoL.
It should be noted, however, that not all of the statistical
differences observed in our multivariate analysis met the
definition of clinical impact (all b coefficients <10); women
were the exception, having substantially worse scores in the
Insomnia domain. Furthermore, the b coefficient for age was
relatively small per 1-year difference, further implying limited
clinical impact. The biggest impact of age can be found in
Physical Functioning (b = 0.56), although a 10-year age
difference would only alter a patient’s score by 5.6 points (on
a scale from 0 to 100).
The factor analyses showed similar results to those of
Gundy et al. [24]: we detected a two-factor model for the
analyses of the QLQ-C30, even though not all the same
items could be retained. We tested this model with CFA,
which resulted in a well-fitting model. Interestingly, the
items that did not load highly onto the factors were single-
item symptom domains such as, Insomnia, Appetite Loss,
Constipation, Diarrhoea, and Financial Difficulties. This
could suggest that they do not contribute as much to
overall HRQoL in these patients. Having a two-factor
model indicating Physical and Mental Health would
increase the usability of the HRQoL questionnaire QLQ-
C30.
The EORTC has published a comprehensive report
containing QLQ-C30 reference values for a wide variety of
cancers [55,56]. Compared with these reference values for
patients with cancer overall [57], BCPP participants had
similar scores. EORTC reference scores for patients with
prostate cancer in stage I–II were similar to patients with
NMIBC in the BCPP (although patients with prostate cancer
did seem to have better Physical Functioning) and scores for
patients with MIBC in the BCPP had similar scores to
patients with stage III–IV prostate cancer (except for Physical
Functioning, which was worse in those with prostate cancer).
Reference values for patients with lung cancer were worse
than for patients with MIBC in the BCPP cohort, with the
exception of Cognitive Functioning values, which were
similar.
As no UK QLQ-C30 data are available for patients with
bladder cancer at or around the time of diagnosis, the aim of
the present study was to provide the first such data. To assess
the generalizability of the present study population and
findings, we compared our study demographics with the West
Midlands Cancer Intelligence Unit data. We found no major
differences with regard to age and gender (data not shown).
In addition, the distribution of patients with NMIBC (78%)
and MIBC (22%) in the BCPP corresponds with that in the
literature from the UK [58]; therefore, the results of the
present study could be used as a reference population for
future research into the HRQoL of patients with bladder
cancer at or around the time of diagnosis in the UK and
beyond.
It is important to note that these data from the BCPP have
been captured from patients presenting in a conventional
manner, having been referred from primary care to secondary
care for the further investigation of symptoms, predominantly
in a haematuria clinic setting; however, up to 18.5% of
patients with bladder cancer present as emergency cases [59],
and it is likely that these patients will have different HRQoL
than those presenting conventionally.
In conclusion, this is the largest NMIBC patient cohort that
has participated in HRQoL research. The study captured the
HRQoL at a unique time point, allowing the identification of
a baseline HRQoL measure. Our findings suggest that
patients’ HRQoL scores at or around the time of bladder
cancer diagnosis are very similar to those of the general
population of Germany and possibly the UK. Only the
domain Role Functioning was found to be significantly better
in patients with NMIBC than those with MIBC at this time
point.
The HRQoL scores given in the present study are interesting
from a clinical point of view. Comparisons with HRQoL
scores at the time of diagnosis give a better insight into any
changes in a patient’s HRQoL attributable to the disease or
treatment.
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